Article Text

AB1108 Identification of Antithrombotic Drugs Related to Total Joint Replacement Using Anonymised Free Text Notes
  1. J.T.H. Nielen1,2,
  2. B. van den Bemt3,4,
  3. A. Boonen5,
  4. P.C. Dagnelie1,
  5. P. Emans6,
  6. A. Lalmohamed2,7,
  7. N. Veldhorst8,
  8. T.-P. van Staa2,
  9. F. de Vries2,8
  1. 1Department of Epidemiology, Maastricht University, Maastricht
  2. 2Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht
  3. 3Department of Pharmacy, Radboud University Medical Center
  4. 4Department of Pharmacy, Sint Maartenskliniek, Nijmegen
  5. 5Department of Rheumatology
  6. 6Department of Orthopaedics, Maastricht University Medical Center, Maastricht
  7. 7Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht
  8. 8Departement of Clinical Pharmacy and Toxicology, Maastricht University Medical Center, Maastricht, Netherlands


Background Intensive antithrombotic treatment is recommended to prevent venous thromboembolic events after total joint replacement (TJR) surgery. Antithrombotic drugs are predominantly dispensed at the hospital. Unfortunately, hospital prescription data is often lacking in general practitioner databases, thereby limiting the possibility to use these rich databases to study the longer term effects in real practice. Un-coded anonymised free text from hospital discharge letters may be used to collect additional information on anticoagulant drug use related to TJR.

Objectives To design and test a method to extract additional information on anticoagulation therapy in patients undergoing TJR from anonymised free text notes in the Clinical Practice Research Datalink (CPRD).

Methods Anticoagulant drug use related to total hip (THR) or total knee replacement (TKR) from January 2008 until October 2012 was identified using both anonymised free text and prescription data. Internal validity of our newly designed method was determined by calculating positive predictive values (PPVs) of positive hits for predefined keywords in a random sample anonymised free text notes. To confirm external validity of our method, the proportions of patients using new oral anticoagulants (NOACs) or low molecular weight heparins (LMWHs) were compared with the proportions that have been reported by the UK National Joint Registry. In order to determine the usefulness of our method, TJR patients were then compared with regards to their status of exposure to antithrombotics.

Results PPVs ranging between 97% - 99% for NOAC or LMWH exposure related to TJR were obtained with our anonymised free text search method, using manual analysis of the surrounding free text as the gold standard. Aspirin users were identified with PPVs ranging from 91% - 95%. Our anonymised free text algorithm increased detection rates by 57%, yielding a total proportion of 18.5% of all THR and 18.6% of all TKR surgeries. Identified users of NOACs and LMWHs were largely similar with regards to age, sex, lifestyle and disease and drug history compared to patients without identified drug use. In contrast, Aspirin users were different as compared to unknown users in particular with regards to a history of ischaemic heart disease.

Conclusions We have developed a useful method to identify additional exposure to NOACs or LMWHs with TJR surgery.

Disclosure of Interest J. Nielen: None declared, B. van den Bemt Grant/research support from: Pfizer, Roche, Speakers bureau: Pfizer, Roche, Abbvie and MSD, A. Boonen Grant/research support from: Amgen Abbvie, Pfizer and Merck, Speakers bureau: Pfizer, UCB and Sandoz, P. Dagnelie: None declared, P. Emans Grant/research support from: Stryker, Active implants, Carbylan Biosurgery, DSM Biomedical, Regentis, Speakers bureau: Biomet and Push braces, A. Lalmohamed Grant/research support from: Netherlands Organisation for Scientific Research (NWO), N. Veldhorst: None declared, T.-P. van Staa: None declared, F. de Vries: None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.